Development of a Pharmacokinetic (PK) Model and Assessment of Patient (PT) Covariate Effects on Dose-Dependent PK following Different Dosing Schedules in Two Phase I Trials of AP23573 (AP), an mTOR Inhabitor

Primary Author: A.A. Desai, University of Chicago, Chicago, IL, Cognigen's Primary Author: G. Fetterly

http://www.asco.org/ac/1,1003,_12-002138,00.asp

Primary Author: A.A. Desai, University of Chicago, Chicago, IL

Event: American Society of Clinical Oncology, May13-17, 2005 Orlando, FL

Other Contributors:

M.J. Ratain, University of Chicago, Chicago, IL

C. Chang, Cognigen Corporation, Buffalo, NY

M. Netsch, Charles River Laboratories Discovery and Development Services, Worcester, MA

H.L. Knowles, ARIAD Pharmaceuticals, Inc., Cambridge, MA

C.L. Bedrosian, ARIAD Pharmaceuticals, Inc., Cambridge, MA

M. Mita, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX

E.Rowinsky, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX

A. Tolcher, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX